Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

,921 Amortization of licensing costs 11,755 1,472 1,472 Amortization of property and equipment 517 125 134 Loss on disposal of property and equipment 11 11 - ------------ -------- -------- (118,881) 3,343 (43,681) Net change in non-cash working capital items Goods and services tax recoverable (299) 185 (28) Prepaid and other current assets (2,548) 734 (571) Advanced clinical trial costs (790) 1,186 (1,976) Accounts payable and accrued liabilities 9,151 (601) 933 Deferred revenue 45,605 45,605 - ------------ -------- -------- (67,762) 50,452 (45,323) ------------ -------- -------- Investing activities Purchase of property and equipment (1,045) (323) (109) Net (purchase of) proceeds from short-term investments (2,614) (86) 3,149 Licensing costs (6,467) - - ------------ -------- -------- (10,126) (409) 3,040 ------------ -------- -------- Financing activities Proceeds from issuance of share capital 178,729 91 44,512 Repurchase of share capital (3,552) (1,434) (36) Share issue costs (12,312) - (3,332)
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015  Platform therapeutic company Symic Biomedical, ... a $1.5M Phase II SBIR grant from the ... its therapeutic agent to reduce arteriovenous fistula (AVF) ... stage renal disease (ESRD) patients undergoing hemodialysis. The ... Diabetes and Digestive and Kidney Diseases (NIDDK), will ...
(Date:8/26/2015)... BEIJING , August 26, 2015 Israel ... DiaCardio wins 1 st place  Wayerz comes ... in Israel by venture capital fund JVP, ... including the US, China , Israel ... America .  Impressive achievement for the Israeli representatives ...
(Date:8/26/2015)... 26, 2015 After litigating and negotiating ... relating to P2i United States patent ... in the United States without any ... of either party. As a result of the parties, settlement, ... California dismissed the case without prejudice. ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical Trial ... with local sponsors in southern California. The Clinical Trial Management Expert CRO seeks to ... regulatory pathways., , Stem Cell Meeting on the Mesa ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6P2i Settles United States Litigation 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... In an address to,shareholders at the company,s ... ) Chairman and CEO David B. Snow Jr. ... designed to deliver strong,continuing earnings growth through 2008 ... specialty pharmacy to retaining and winning,customers, and advanced ...
... May 22 /PRNewswire-FirstCall/ - In accordance with the,terms ... Inc.,"Atrium" (TSX: ATB) today announced that it has ... Chemicals division for total proceeds of,US$166.4 million in ... is now a health and nutrition pure-play and ...
... CT Injection System Technology Detects Extravasations during CT ... ... MEDRAD, INC., announced today,that its XDS(TM) Extravasation Detector has ... a technology that aids in the,detection of leaking intravenous contrast ...
Cached Biology Technology:Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 2Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 3Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 4MEDRAD(R) XDS(TM) Extravasation Detector Wins Medical Design Excellence Award 2MEDRAD(R) XDS(TM) Extravasation Detector Wins Medical Design Excellence Award 3
(Date:8/24/2015)... 2015 The consulting company Frost & ... manufacturer DERMALOG and its customized solutions and products for ... of the Year Award". DERMALOG is particularly successful with a ... -Cross reference: Picture is available at AP Images ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... fond of talking about it as are politicians, economists ... The problem is that the term sustainability can refer ... at the Technische Universitaet Muenchen have shed light on ... science they have managed to give the term "sustainability" ...
... School of Medicine found that women may have a slightly higher ... acute coronary syndrome (ACS), but that these differences appear to be ... study, published in the August 26, 2009 issue of the ... however that overall there was no significant difference in mortality observed ...
... use wireless sensors, which can monitor chemical processes or ... wireless network. Still, many facilities that could benefit ... use a wired network instead, because the reliability, speed ... do not meet their needs. The U.S. ...
Cached Biology News:New tools for sustainable farming 2New tools for sustainable farming 3Study finds women slightly more likely to die than men in the 30 days following a heart attack 2SRNL, automakers to develop high-performance wireless sensors networks 2SRNL, automakers to develop high-performance wireless sensors networks 3
...
2ndGen Predilute antibody for staining tissue sections. Optimized for use with Zymeds Histostain-PLUS, NBA, HistoST5050, and Cap-Plus IHC Kits.Labeling: ASR...
... degradation of single-stranded DNA and RNA endonucleolytically ... nuclease prefers ssDNA over dsDNA by 30,000-fold, ... double-stranded DNA from both ends (1,2). Mung ... mapping studies (3,4), for flushing staggered ends ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
Biology Products: